Moderator: SABCS Co-director Virginia Kaklamani, MD, leader of the Breast Cancer Program at the Cancer Therapy & Research Center and professor of medicine at the UT Health Science Center San Antonio Capecitabine Improved Outcomes for Breast Cancer Patients With Residual Disease After Presurgery Chemotherapy; Women With Luminal A Subtype of Breast Cancer Did Not Benefit From Adjuvant Chemotherapy; Denosumab Improves Disease-free Survival for Postmenopausal Patients With HR-positive Breast Cancer; and Pathologic Complete Response to Presurgery Chemotherapy Improves Survival For Patients With Triple-negative Breast Cancer.